🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I’ve waited YEARS for this moment — James Chavez’s FIRST DAY as an official member of the Majeti Lab!! 🥳☕️

🧫🧪📡📡📡Hi all - if you have EXCITING, UNPUBLISHED work in the hematopoiesis field that you want to present at the myeloid workshop, get in touch!!!

Happy to share our work in Journal of Clinical Investigation on RUNX1 loss in leukemic progression. Using primary human samples, we find a targetable dependency of RUNX1-mutant leukemias on IL-3/JAK/STAT signaling. Magnificent work by Amy Fan! Check it out ➡️ jci.org/articles/view/…

How can #ClonalHematopoiesis make solid #tumors grow faster? Find out in our new story by Yang Feng Yang Feng et al. out today in Journal of Experimental Medicine (bit.ly/3KVoJTz), or read an excellent summary (bit.ly/3ORtoqR). UF Health Cancer Center UF_Pharmacology

Happy to share our review on #chronic_Inflammation in normal and mutant #HSC, summarizing insights from the 2023 ISEH webinar. Thanks to our co-authors Katherine King MDPhD & Eric Pietras and ISEH New Investigator Committee @camille_malouf Linde Miles. sciencedirect.com/science/articl…

Our latest work, led by Philipp Rauch and Jk Gopakumar in collaboration with Ben Ebert, Peter Libby, and others, on mouse models of atherosclerosis with loss of Tet2 or Dnmt3a! Really fortunate to be able to work with such a talented group. rdcu.be/dlcy1

First of many this year….my first-first author publication is out in the world-preprint below! And my first oral presentation ASH this year. So much to look forward to- none possible without the support of Jordan Lab Daniel Pollyea CU Anschutz Hematology/Oncology Fellowship CU Anschutz Division of Hematology #ASH23

Excited to share our review article in Blood Journal on the Causes and Consequences of Clonal Hematopoeisis This was fun to write. Hope it summarizes the state of the field to date. As always, shout out to the 🐐, Ben Ebert! ashpublications.org/blood/article/…

#ASH2023 attendees don’t miss out on these talks from my colleagues in the Majeti Lab ! Stellar science from stellar scientists!

Congratulations to the labs newest PhD candidates James Chavez (James Chavez), Cassandra Stawicki (Cassandra Stawicki) and Emma Heaton (Emma Heaton), who all passed their qualifying exams over the past weeks!

Congrats on a beautiful article by @cellseywoodruff in our lab - out today in nature. Organize your –80 °C freezer to save time and prevent frozen fingertips nature.com/articles/d4158… New Organizō freezer inventory template just dropped: organizolife.com/downloads #TheLabEdit

I wrote a blog post about scientific racism and the AllofUsResearch figure illustrating their ancestry analysis. The post was inspired by a presentation of Delaney Sullivan at our lab DEI meeting organized by Nikhila Swarna (Nikki) last week. liorpachter.wordpress.com/2024/02/26/all… cc Josh Denny

Worth the read.

Delighted and honored to share that I was awarded the NSF GRFP. Extremely thankful for my current Majeti Lab and former mentors Eric Pietras Jason Lee as well as my graduate program Stanford Cancer Biology PhD Program. Congratulations to all other recipients and to all of the honorable mentions!

Delighted to share our new work in Blood Journal led by the outstanding and creative Dr. Kira Young! Kira embarked on a journey to understand why individual organisms exhibit natural variation in hematopoietic aging phenotypes. Interesting question! doi.org/10.1182/blood.…

ISEH is proud to announce the winners of our 2024 Society Awards! Scientific Award Winners: Emmanuelle Passegué, Ravindra 'Ravi' Majeti and Robert Signer Leadership Award Winners: Ross Levine and Katherine King Read more about this year's winners here 👉 simplyblood.org

“If I cannot be a child, then let me be a scientist… because scientists have boundless curiosity and an unrestrained imagination.” med.stanford.edu/news/all-news/…

Dr. Minhajuddin at CU School of Medicine and team show that venetoclax/dasatinib is a leukemia stem cell (LSC) selective regimen in blast phase CML and that disrupting LIPA and fatty acid transport enhances venetoclax/dasatinib response in targeting LSCs. bit.ly/3xzrHK5